TiGenix NV TIG Medical Equipment Deals and Alliances Profile Report Updated...
SummaryTiGenix NV TiGenix is a biopharmaceutical company that develops and commercializes novel therapeutics. Its product portfolio includes AlloCSC01 AlloCSC02 Cx611 and Cx601. The company develops...
View ArticleSeres Therapeutics Reports Third Quarter 2017 Financial Results and Provides...
Positive results from SER287 Phase 1b study in mildtomoderate Ulcerative Colitis; Company to move program into further development Company awarded CARBX grant to advance SER155 for allogeneic stem cell...
View ArticleColon cancer breakthrough could lead to prevention and the foods that can help
Colon cancer Crohn's and other diseases of the gut could be better treated or even prevented thanks to a new link between inflammation and a common cellular process established by the University of...
View ArticleRedHill Biopharma Prices Public Offering of its American Depositary Shares
TELAVIV Israel and RALEIGH N.C. Nov. 08 2017 GLOBE NEWSWIRE RedHill Biopharma Ltd. NASDAQRDHL TelAviv Stock ExchangeRDHL "RedHill" or the "Company" a specialty...
View ArticleCrohn's Disease CD Market Insights Epidemiology and Market Forecast 2025...
DelveInsight's Crohn's Disease CD Market Insights Epidemiology and Market Forecast Market Insights Epidemiology and Market Forecast 2025 report provides an overview of the disease and in depth research...
View ArticleRedHill Biopharma Ltd. RedHill Biopharma Announces Last Patient Enrolled in...
Topline results are expected to be announced in mid2018 The Phase III study evaluating RHB104 for Crohn's disease MAP US study is a randomized doubleblind placebocontrolled study tha...
View ArticleRedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with...
Topline results are expected to be announced in mid2018Â The Phase III study evaluating RHB104 for Crohn's disease MAP US study is a randomized doubleblind placebocontrolled study that is...
View ArticleNeedlefree biologics Takeda & Portal develop delivery tech for Crohns
Takeda has partnered with Portal Instruments to develop a needlefree drug delivery device for biologic medicines starting with the formers Entyvio vedolizumab.
View ArticleAtypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine...
Atypical Chemokine Receptor 3 CXC Chemokine Receptor Type 7 or Chemokine Orphan Receptor 1 or G Protein Coupled Receptor 159 or G Protein Coupled Receptor RDC1 Homolog or GPR159 or CXCR7 or ACKR3...
View ArticleImmune Pharmaceuticals Inc IMNP Pharmaceuticals Healthcare Deals and...
SummaryImmune Pharmaceuticals Inc Immune Pharma formerly EpiCept Corp is a biotechnology company that develops antibody therapeutics for the treatment of patients with inflammatory diseases and cancer....
View ArticleTaiwanJ Pharmaceuticals Co Ltd 6549 Financial and Strategic SWOT Analysis...
SummaryTaiwanJ Pharmaceuticals Co Ltd TaiwanJ is a pharmaceutical company that develops and commercialize firstinclass small molecules as TLR4 antagonists. The company's TLR4 is a transmembrane protein...
View ArticleRedHill Biopharma Reports 2017 Third Quarter Financial Results
RedHill maintains a debtfree balance sheet with $39.6 million in cash1Âat the end of the third quarter of 2017 In addition an underwritten public offering of the Company's American Depositary...
View ArticleCrohn's Disease CD Epidemiology Forecast to 2025 Report Updated 10102017...
DelveInsight Crohn's Disease CD Epidemiology Forecast To 2025 provides an overview of the epidemiology trends of Crohn's Disease CD in seven major markets US France Germany Italy Spain UK and Japan. It...
View ArticleRedHill Biopharma Announces Closing of Public Offering of its American...
TELAVIV Israel and RALEIGH N.C. Nov. 13 2017 GLOBE NEWSWIRE RedHill Biopharma Ltd. NASDAQRDHL TelAviv Stock ExchangeRDHL "RedHill" or the "Company" a specialty...
View ArticleBoehringer bags first biosimilar approval in the EU
Boehringer Ingelheim has won its first biosimilar approval in Europe with authorisation of Cyltezo for a range of chronic inflammatory conditions including rheumatoid arthritis psoriatic arthritis...
View ArticleRedHill Biopharma Ltd RDHL Financial and Strategic SWOT Analysis Review...
RedHill Biopharma Ltd RDHL Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by...
View ArticleQueens Medical Associates Adds New Physician
Dr. Abhisek Swaika joins leading oncology and hematology practiceFresh Meadows NY PRWEB November 14 2017 Queens Medical Associates a preeminent cancer care facility and infusion center specializing in...
View ArticleRedHill Biopharma concludes enrolment in Crohns disease trial
RedHill Biopharma has finished patient enrolment in a Phase III clinical trial MAP US of RHB104 being evaluated for the...Read More...The post RedHill Biopharma concludes enrolment in Crohns disease...
View ArticleTipping the balance How one strain of bacteria affects its neighbors in...
American Association for the Advancement of Science A new study suggests a single strain of bacteria can reconfigure entire communities of microbes that make up the gut microbiota.
View ArticleBiotech Targets 'Blockbuster' Markets; LessAddictive Opioid Painkiller Set...
Source John McCamant for Streetwise Reports 11152017 Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that in...
View Article